Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial
Marc Cohen, Glenn N. Levine, Karen S. Pieper, Lan Lan, Elliott M. Antman, Philip E. Aylward, Harvey D. White, Neal Kleiman, Robert M. Califf, Kenneth W. Mahaffey
Research output: Contribution to journal › Article › peer-review
19
!!Link opens in a new tab
Scopus
citations